# Health Ministry Updates Guidelines for Medical Cannabis Prescription | The Jerusalem Post > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/medical-cannabis-guidelines-update-israel-health-ministry/ > **Published:** 2026-05-04T10:34:19-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:56:24-04:00 > **Clinical Summary:** Explore the medical cannabis guidelines update by Israel's Health Ministry improving prescribing standards for PTSD and chronic pain treatment. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. Policy[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)PainPTSDAging Why This Matters Israel’s updated [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) guidelines establish clearer prescribing standards that can help clinicians make evidence-based decisions about patient eligibility for cannabis treatment, particularly for conditions like PTSD and [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) in elderly populations. This regulatory clarity reduces prescribing uncertainty and helps patients access cannabis through formal clinical pathways rather than unregulated alternatives. When guidelines are formalized at the health ministry level, it signals institutional confidence in cannabis as a therapeutic option and may facilitate insurance coverage and [clinical documentation](https://cedclinic.com/ethical-legal-dilemmas-cannabis-use/) that improves patient outcomes and safety monitoring. Clinical Summary Israel’s Health Ministry has updated its guidelines for medical cannabis prescription, reflecting a decade of regulatory evolution since the initial government decision to permit medical and research use. The updated guidelines appear to expand access considerations across diverse patient populations, including elderly patients and those with conditions such as PTSD, suggesting a broadening of the clinical indications recognized for [cannabinoid therapy](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/). This regulatory development signals a shift toward more formalized clinical pathways for cannabis prescription, which may establish clearer standards for patient eligibility, dosing protocols, and monitoring practices. For clinicians in jurisdictions following Israel’s regulatory model, these guidelines could inform evidence-based decision-making around cannabis recommendations and help standardize prescribing practices that have historically lacked clear clinical frameworks. Practitioners should monitor how these international guideline updates translate into their own regulatory environments, as they may influence clinical protocols for conditions like PTSD and [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) in geriatric populations where cannabis is increasingly considered as a treatment option. Dr. Caplan’s Take “When regulatory bodies like Israel’s Health Ministry update medical cannabis guidelines, what actually matters to me in clinic is whether those updates reflect current evidence on efficacy and safety, not just political shifts—and frankly, most guidelines still lag behind what we’re learning about [cannabinoid therapy](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) for conditions like PTSD and [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) in our patient populations.” Clinical Perspective Israel’s updated medical cannabis guidelines represent an important regulatory evolution, though healthcare providers should recognize that these recommendations emerge from a healthcare system with different clinical infrastructure and patient populations than many Western settings. The inclusion of conditions like PTSD and chronic pain reflects growing international recognition of potential therapeutic applications, yet the evidence base remains heterogeneous across indications, with robust data for some conditions (such as certain seizure disorders) but more limited evidence for others. Providers should note that guideline updates in one country do not necessarily translate directly to their own jurisdictions, which may have distinct regulatory pathways, reimbursement structures, and access limitations. When counseling patients about medical cannabis—whether locally available or not—clinicians should contextualize these guidelines within their own evidence appraisals, remain attentive to potential drug interactions and individual risk factors (particularly in elderly populations and those with substance use history), and document discussions thoroughly given the evolving legal and 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Health%20Ministry%20updates%20guidelines%20for%20medical%20cannabis%20perscription%20%7C%20The%20Jerusalem%20Post%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fhealth-ministry-updates-guidelines-for-medical-cannabis-perscription-the-jerusalem-post%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fhealth-ministry-updates-guidelines-for-medical-cannabis-perscription-the-jerusalem-post%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Health%20Ministry%20updates%20guidelines%20for%20medical%20cannabis%20perscription%20%7C%20The%20Jerusalem%20Post%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fhealth-ministry-updates-guidelines-for-medical-cannabis-perscription-the-jerusalem-post%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Healthcare Professionals Agree Cannabis Has "Legitimate Therapeutic Uses"](https://cedclinic.com/healthcare-professionals-agree-cannabis-has-legitimate-therapeutic-uses/) Explore expert consensus on the therapeutic potential of cannabis across various medical conditions. [Learn More](https://cedclinic.com/healthcare-professionals-agree-cannabis-has-legitimate-therapeutic-uses/) [Will the Medical Cannabis Market Grow as More Countries Approve](https://cedclinic.com/will-the-medical-cannabis-market-grow-as-more-countries-approve/) Insights into the expanding global medical cannabis market and regulatory trends influencing growth. [Read Insights](https://cedclinic.com/will-the-medical-cannabis-market-grow-as-more-countries-approve/) [Cannabis Warning Label Regulations and Characteristics in US States](https://cedclinic.com/cannabis-warning-label-regulations-and-characteristics-in-us-states-with-medical-and/) A review of cannabis product labeling regulations and their impact on patient safety and compliance. [Explore Details](https://cedclinic.com/cannabis-warning-label-regulations-and-characteristics-in-us-states-with-medical-and/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).